Targets › LYN
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology, Metabolic and endocrine; next expected readout Dec 2027.
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors and plays an important role in the regulation of innate and adaptive immune responses, hematopoiesis, responses to growth factors and cytokines, integrin signaling, but also responses to DNA damage and genotoxic agents. Functions primarily as negative regulator, but can also function as activator, depending on the context. (UniProt, P07948)
Open in Phaseline: the race on LYN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Alberta | MTX228 (Tolimidone) Lyn kinase activator | LYN | Phase 2 | Type 1 Diabetes Mellitus | Dec 2027 |
| Baylor College of Medicine | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 2 | Chronic Myeloid Leukemia | Nov 2028 |
| Children's Oncology Group | Bosutinib Tyrosine-protein kinase ABL inhibitor; Tyrosine-protein kinase SRC inhibitor; Tyrosine-protein kinase HCK inhibitor | ABL1, SRC, HCK, LYN, BCR | Phase 1 | Philadelphia Chromosome Positive CML | Jul 2028 |
Chronic Myeloid Leukemia (1) Philadelphia Chromosome Positive CML (1) Type 1 Diabetes Mellitus (1)
small molecule (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.